GAP

Feb 28, 2024 | Jessica Kim Cohen NEW YORK – Results from blood-based biomarker tests correlated with the presence of beta-amyloid detected using established Alzheimer’s disease diagnostics, according to a study published Wednesday. PET scans and cerebrospinal fluid (CSF) analyses are highly accurate and established methods of identifying elevated levels of beta-amyloid, a hallmark of Alzheimer’s. However, these […]

The results of the Bio-Hermes study appear in Alzheimer’s & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over […]

At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]

For the first time in 15 years, there are new Alzheimer’s drug treatments on the horizon that are expected to seek regulatory approval by the FDA and leading experts are increasely optimistic that a major breakthrough in Alzheimer’s research will occur within the next five years. We are at a moment of peak opportunity – […]